Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 392

1.

Prostate Cancers Detected by Magnetic Resonance Imaging-Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies.

Zhao Y, Deng FM, Huang H, Lee P, Lepor H, Rosenkrantz AB, Taneja S, Melamed J, Zhou M.

Arch Pathol Lab Med. 2018 Jul 2. doi: 10.5858/arpa.2017-0410-OA. [Epub ahead of print]

PMID:
29965785
2.

Long-Term Natural History of Lower Urinary Tract Symptoms Following Radical Retropubic Prostatectomy: A Prospective 15 Year Longitudinal Study.

Xu AJ, Taksler GB, Llukani E, Lepor H.

Urology. 2018 Jun 25. pii: S0090-4295(18)30579-X. doi: 10.1016/j.urology.2018.06.014. [Epub ahead of print]

PMID:
29953883
3.

Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis.

Weng MW, Lee HW, Park SH, Hu Y, Wang HT, Chen LC, Rom WN, Huang WC, Lepor H, Wu XR, Yang CS, Tang MS.

Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6152-E6161. doi: 10.1073/pnas.1804869115. Epub 2018 Jun 18.

4.

The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection during 4 Years.

Meng X, Rosenkrantz AB, Huang R, Deng FM, Wysock JS, Bjurlin M, Huang WC, Lepor H, Taneja SS.

J Urol. 2018 Jun 7. pii: S0022-5347(18)43348-4. doi: 10.1016/j.juro.2018.06.012. [Epub ahead of print]

PMID:
29886090
5.

Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015.

Loeb S, Byrne N, Makarov DV, Lepor H, Walter D.

JAMA. 2018 Jun 5;319(21):2231-2233. doi: 10.1001/jama.2018.5616. No abstract available.

PMID:
29800017
6.

Long-Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15-Year Longitudinal Study.

Xu AJ, Taksler GB, Llukani E, Lepor H.

J Urol. 2018 May 7. pii: S0022-5347(18)43101-1. doi: 10.1016/j.juro.2018.05.005. [Epub ahead of print]

PMID:
29746859
7.

Health state utilities among contemporary prostate cancer patients on active surveillance.

Loeb S, Curnyn C, Walter D, Fagerlin A, Siebert U, Mühlberger N, Braithwaite RS, Schwartz MD, Lepor H, Sedlander E.

Transl Androl Urol. 2018 Apr;7(2):197-202. doi: 10.21037/tau.2017.03.80.

8.

E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells.

Lee HW, Park SH, Weng MW, Wang HT, Huang WC, Lepor H, Wu XR, Chen LC, Tang MS.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1560-E1569. doi: 10.1073/pnas.1718185115. Epub 2018 Jan 29.

9.

Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer.

Alexander J, Kendall J, McIndoo J, Rodgers L, Aboukhalil R, Levy D, Stepansky A, Sun G, Chobardjiev L, Riggs M, Cox H, Hakker I, Nowak DG, Laze J, Llukani E, Srivastava A, Gruschow S, Yadav SS, Robinson B, Atwal G, Trotman LC, Lepor H, Hicks J, Wigler M, Krasnitz A.

Cancer Res. 2018 Jan 15;78(2):348-358. doi: 10.1158/0008-5472.CAN-17-1138. Epub 2017 Nov 27.

PMID:
29180472
10.

Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings.

Bjurlin MA, Rosenkrantz AB, Sarkar S, Lepor H, Huang WC, Huang R, Venkataraman R, Taneja SS.

Urology. 2018 Feb;112:112-120. doi: 10.1016/j.urology.2017.09.035. Epub 2017 Nov 16.

PMID:
29155186
11.

The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer.

Kenigsberg AP, Llukani E, Deng FM, Melamed J, Zhou M, Lepor H.

Urology. 2018 Feb;112:121-125. doi: 10.1016/j.urology.2017.10.014. Epub 2017 Oct 20.

PMID:
29061480
12.

Informational needs during active surveillance for prostate cancer: A qualitative study.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Ciprut S, Sedlander E.

Patient Educ Couns. 2018 Feb;101(2):241-247. doi: 10.1016/j.pec.2017.08.022. Epub 2017 Sep 1.

PMID:
28886974
13.

Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions.

Loeb S, Zhou Q, Siebert U, Rochau U, Jahn B, Mühlberger N, Carter HB, Lepor H, Braithwaite RS.

Eur Urol. 2017 Dec;72(6):899-907. doi: 10.1016/j.eururo.2017.07.018. Epub 2017 Aug 23.

PMID:
28844371
14.

Multiparametric magnetic resonance imaging identifies significant apical prostate cancers.

Kenigsberg AP, Tamada T, Rosenkrantz AB, Llukani E, Deng FM, Melamed J, Zhou M, Lepor H.

BJU Int. 2018 Feb;121(2):239-243. doi: 10.1111/bju.13987. Epub 2017 Sep 5.

PMID:
28805295
15.

Multi-parametric MRI imaging of the prostate-implications for focal therapy.

Wysock JS, Lepor H.

Transl Androl Urol. 2017 Jun;6(3):453-463. doi: 10.21037/tau.2017.04.29. Review.

16.

Magnetic resonance imaging in prostate cancer.

Bjurlin MA, Rosenkrantz AB, Lepor H, Taneja SS.

Transl Androl Urol. 2017 Jun;6(3):343-344. doi: 10.21037/tau.2017.05.16. No abstract available.

17.

Editorial Comment.

Lepor H.

J Urol. 2017 Aug;198(2):343-344. doi: 10.1016/j.juro.2017.03.143. Epub 2017 May 15. No abstract available.

PMID:
28521143
18.

Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.

Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303. doi: 10.1016/j.ijrobp.2017.02.004. Epub 2017 Feb 12.

19.

Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies.

Fusco F, Creta M, Imperatore V, Longo N, Imbimbo C, Lepor H, Mirone V.

Adv Ther. 2017 Apr;34(4):773-783. doi: 10.1007/s12325-017-0504-0. Epub 2017 Mar 2. Review.

PMID:
28255867
20.

Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy.

Llukani E, Lepor H.

BJU Int. 2017 Oct;120(4):505-510. doi: 10.1111/bju.13816. Epub 2017 Mar 14.

PMID:
28220652
21.

Prostate Cancer Academy 2016: Presentation summaries.

Crawford ED, Albala DM, Wysocki JS, Lepor H, Ross AE, Finkelstein SE, Keane T, Freedland S, Harris R, Shore ND, Ryan CJ.

Rev Urol. 2016;18(4):205-213. doi: 10.3909/riuPCA2016. No abstract available.

22.

Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.

Mirhadi AJ, Zhang Q, Hanks GE, Lepor H, Grignon DJ, Peters CA, Rosenthal SA, Zeitzer K, Radwan JS, Lawton C, Parliament MB, Reznik RS, Sandler HM.

Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):511-515. doi: 10.1016/j.ijrobp.2016.11.002. Epub 2016 Nov 8.

23.

Surgical Treatment of Prostate Carcinoma.

Lepor H.

J Urol. 2017 Feb;197(2S):S41-S42. doi: 10.1016/j.juro.2016.10.084. Epub 2016 Dec 20. No abstract available.

PMID:
28010978
24.
25.

Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy.

Fenstermaker M, Mendhiratta N, Bjurlin MA, Meng X, Rosenkrantz AB, Huang R, Deng FM, Zhou M, Huang WC, Lepor H, Taneja SS.

Urology. 2017 Jan;99:174-179. doi: 10.1016/j.urology.2016.08.022. Epub 2016 Aug 22.

PMID:
27562202
26.

Risk of Small Bowel Obstruction After Robot-Assisted vs Open Radical Prostatectomy.

Loeb S, Meyer CP, Krasnova A, Curnyn C, Reznor G, Kibel AS, Lepor H, Trinh QD.

J Endourol. 2016 Dec;30(12):1291-1295.

PMID:
27615204
27.

Qualitative study on decision-making by prostate cancer physicians during active surveillance.

Loeb S, Curnyn C, Fagerlin A, Braithwaite RS, Schwartz MD, Lepor H, Carter HB, Sedlander E.

BJU Int. 2017 Jul;120(1):32-39. doi: 10.1111/bju.13651. Epub 2016 Oct 2.

28.

New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.

Valerio M, Cerantola Y, Eggener SE, Lepor H, Polascik TJ, Villers A, Emberton M.

Eur Urol. 2017 Jan;71(1):17-34. doi: 10.1016/j.eururo.2016.08.044. Epub 2016 Aug 29. Review.

PMID:
27595377
29.

Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition.

Rosenkrantz AB, Khasgiwala A, Doshi AM, Ream JM, Taneja SS, Lepor H.

Abdom Radiol (NY). 2017 Jan;42(1):290-297. doi: 10.1007/s00261-016-0881-x.

30.

Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia.

Lepor H.

Urol Clin North Am. 2016 Aug;43(3):311-23. doi: 10.1016/j.ucl.2016.04.009. Review.

PMID:
27476124
31.

Editorial Comment.

Lepor H.

Urology. 2016 Jul;93:74. doi: 10.1016/j.urology.2016.02.058. Epub 2016 May 11. No abstract available.

PMID:
27179945
32.

Practical Barriers to Obtaining Pre-Biopsy Prostate MRI: Assessment in Over 1,500 Consecutive Men Undergoing Prostate Biopsy in a Single Urologic Practice.

Rosenkrantz AB, Lepor H, Huang WC, Taneja SS.

Urol Int. 2016;97(2):247-8. doi: 10.1159/000446003. Epub 2016 Apr 29. No abstract available.

PMID:
27160263
33.

Testosterone Deficiency and the Prostate.

Alukal JP, Lepor H.

Urol Clin North Am. 2016 May;43(2):203-8. doi: 10.1016/j.ucl.2016.01.013. Review.

PMID:
27132577
34.

Editorial Comment.

Lepor H.

Urology. 2016 May;91:116-7. doi: 10.1016/j.urology.2015.12.076. No abstract available.

PMID:
27107188
35.

Teaching Hospitals and the Disconnect Between Technology Adoption and Comparative Effectiveness Research: The Case of the Surgical Robot.

Makarov DV, Li H, Lepor H, Gross CP, Blustein J.

Med Care Res Rev. 2017 Jun;74(3):369-376. doi: 10.1177/1077558716642690. Epub 2016 Mar 30.

PMID:
27034439
36.

How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.

Loeb S, Walter D, Curnyn C, Gold HT, Lepor H, Makarov DV.

J Urol. 2016 Sep;196(3):721-6. doi: 10.1016/j.juro.2016.02.2963. Epub 2016 Mar 2.

37.

The Challenge for Urologists Is to Screen, Detect, and Treat Prostate Cancer "Smarter": Will Ablative Technology Result in Smarter Treatment?

Lepor H.

Eur Urol. 2016 Sep;70(3):456-7. doi: 10.1016/j.eururo.2016.01.024. Epub 2016 Jan 20. No abstract available.

PMID:
26803477
38.

Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.

Wysock JS, Mendhiratta N, Zattoni F, Meng X, Bjurlin M, Huang WC, Lepor H, Rosenkrantz AB, Taneja SS.

BJU Int. 2016 Oct;118(4):515-20. doi: 10.1111/bju.13427. Epub 2016 Feb 25.

39.

The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy.

Sivarajan G, Borofsky MS, Shah O, Lingeman JE, Lepor H.

Rev Urol. 2015;17(3):140-9.

40.

Size-adjusted Quantitative Gleason Score as a Predictor of Biochemical Recurrence after Radical Prostatectomy.

Deng FM, Donin NM, Pe Benito R, Melamed J, Le Nobin J, Zhou M, Ma S, Wang J, Lepor H.

Eur Urol. 2016 Aug;70(2):248-53. doi: 10.1016/j.eururo.2015.10.026. Epub 2015 Oct 30.

41.

Cigarette side-stream smoke lung and bladder carcinogenesis: inducing mutagenic acrolein-DNA adducts, inhibiting DNA repair and enhancing anchorage-independent-growth cell transformation.

Lee HW, Wang HT, Weng MW, Chin C, Huang W, Lepor H, Wu XR, Rom WN, Chen LC, Tang MS.

Oncotarget. 2015 Oct 20;6(32):33226-36. doi: 10.18632/oncotarget.5429.

42.

A prospective comparative analysis of the accuracy of HistoScanning and multiparametric magnetic resonance imaging in the localization of prostate cancer among men undergoing radical prostatectomy.

Orczyk C, Rosenkrantz AB, Deng FM, Melamed J, Babb J, Wysock J, Kheterpal E, Huang WC, Stifelman M, Lepor H, Taneja SS.

Urol Oncol. 2016 Jan;34(1):3.e1-8. doi: 10.1016/j.urolonc.2015.07.004. Epub 2015 Aug 31.

PMID:
26338414
43.

Prebiopsy MRI and MRI-ultrasound Fusion-targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies.

Mendhiratta N, Meng X, Rosenkrantz AB, Wysock JS, Fenstermaker M, Huang R, Deng FM, Melamed J, Zhou M, Huang WC, Lepor H, Taneja SS.

Urology. 2015 Dec;86(6):1192-8. doi: 10.1016/j.urology.2015.07.038. Epub 2015 Aug 31.

44.

Reply: To PMID 26163812.

Lepor H.

Urology. 2015 Oct;86(4):788-9. doi: 10.1016/j.urology.2015.05.036. Epub 2015 Aug 29. No abstract available.

PMID:
26324001
45.

Is Targeted Therapy of Prostate Cancer Ready for Prime Time?

Lepor H.

Eur Urol. 2016 Feb;69(2):221-2. doi: 10.1016/j.eururo.2015.06.049. Epub 2015 Jul 16. No abstract available.

PMID:
26189690
46.

10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era.

Mendhiratta N, Lee T, Prabhu V, Llukani E, Lepor H.

Urology. 2015 Oct;86(4):783-8. doi: 10.1016/j.urology.2015.05.034. Epub 2015 Jul 9.

PMID:
26163812
47.

Likert score 3 prostate lesions: Association between whole-lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsy.

Rosenkrantz AB, Meng X, Ream JM, Babb JS, Deng FM, Rusinek H, Huang WC, Lepor H, Taneja SS.

J Magn Reson Imaging. 2016 Feb;43(2):325-32. doi: 10.1002/jmri.24983. Epub 2015 Jul 1.

PMID:
26131965
48.

Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.

Meng X, Rosenkrantz AB, Mendhiratta N, Fenstermaker M, Huang R, Wysock JS, Bjurlin MA, Marshall S, Deng FM, Zhou M, Melamed J, Huang WC, Lepor H, Taneja SS.

Eur Urol. 2016 Mar;69(3):512-7. doi: 10.1016/j.eururo.2015.06.005. Epub 2015 Jun 22.

49.

Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification.

Mendhiratta N, Rosenkrantz AB, Meng X, Wysock JS, Fenstermaker M, Huang R, Deng FM, Melamed J, Zhou M, Huang WC, Lepor H, Taneja SS.

J Urol. 2015 Dec;194(6):1601-6. doi: 10.1016/j.juro.2015.06.078. Epub 2015 Jun 19.

PMID:
26100327
50.

Supplemental Content

Support Center